Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global 
      biopharmaceutical company, today announced final approval from the U.S. 
      Food and Drug Administration (FDA) for its Abbreviated New Drug 
      Application (ANDA) for Fosphenytoin Sodium Injection, 100 mg, 2 mL and 
      500 mg, 10 mL vials, USP, the generic equivalent of Pfizer’s 
      Cerebyx®. According 
      to IMS, sales in 2006 of fosphenytoin sodium injection in the United 
      States exceeded $73 million. The company expects to commence marketing 
      of fosphenytoin sodium injection in August 2007. The product is AP 
      rated, preservative-free and latex-free.
    
    
      Fosphenytoin Sodium Injection is indicated for short-term parenteral 
      administration when other means of phenytoin administration are 
      unavailable, inappropriate or deemed less advantageous. The safety and 
      effectiveness of Fosphenytoin Sodium Injection in this use has not been 
      systematically evaluated for more than five days.
    
    
      Fosphenytoin Sodium Injection can be used for the control of generalized 
      convulsive status epilepticus and the prevention and treatment of 
      seizures occurring during neurosurgery. It can also be substituted, 
      short-term, for oral phenytoin.
    
    
      About Abraxis BioScience, Inc.
    
    
      Abraxis BioScience, Inc. is an integrated global biopharmaceutical 
      company dedicated to meeting the needs of critically ill patients. The 
      company develops, manufactures and markets one of the broadest 
      portfolios of injectable products and leverages revolutionary technology 
      such as its nab™ platform to discover 
      and deliver breakthrough therapeutics that transform the treatment of 
      cancer and other life-threatening diseases. The first FDA approved 
      product to use this nab platform, ABRAXANE®, 
      was launched in 2005 for the treatment of metastatic breast cancer. 
      Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For 
      more information about the company and its products, please visit www.abraxisbio.com.
    
    
      Cerebyx® is a 
      registered trademark of Pfizer Inc.